Waters Corporation (NYSE: WAT) has reported its first-quarter 2026 financial results, marking a transformative period for the company following its combination with the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company (BD). The company exceeded expectations, reporting total revenue of $1.267 billion and raising its full-year 2026 organic constant currency revenue growth guidance to 6.5%–8.0%.
For lab managers, this quarter highlights a decisive move by Waters to expand its footprint beyond traditional chromatography and mass spectrometry into specialty diagnostics and high-volume clinical testing.
A New Chapter: Biosciences and Advanced Diagnostics
The Q1 results are the first to reflect the newly formed divisions within Waters: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences. The Biosciences and Diagnostic Solutions units generated $520 million in revenue since the close of the transaction on February 9, 2026—exceeding internal guidance by $40 million.
"Our Biosciences and Advanced Diagnostics Divisions are off to a strong start," said Dr. Udit Batra, President and CEO of Waters Corporation. "We are seeing significant improvement in growth rates due to increased execution discipline and a sharper focus on upcoming new product launches."
Key developments for the lab community include:
- Advanced Diagnostics Division (ADx): This division now houses the former BD Diagnostic Solutions business alongside Waters' existing clinical unit. The focus is on high-value diagnostic workflows in regulated clinical settings, including microbiology, molecular diagnostics, and LC-MS-based multiplex testing.
- Waters Biosciences: Formerly BD Biosciences, this unit focuses on cellular sorting and analysis, including flow cytometry instruments and reagents. This expansion aligns with broader industry trends, in which suppliers are reporting a turning point in recovery and transformation through portfolio diversification.
New Product Momentum: Automation and Detection
Despite the complex integration process, Waters continues to roll out technology aimed at improving lab productivity and data quality.
- omniDAWN MALS Detector: In April 2026, Waters debuted the industry-first extended-range Multi Angle Light Scattering (MALS) detector for UHPLC/UPLC. This tool is designed for the rapid characterization of large molecules, targeting viral vectors, lipid nanoparticles, and protein aggregates.
- Charged Aerosol Detector (CAD): A new CAD optimized for Empower Software is expected to begin shipments by April 2026. It expands capabilities for measuring analytes with little or no UV absorption—critical for labs in pharmaceutical, food, and environmental testing.
- FDA Clearance for Cervical Cancer Screening: Waters recently announced FDA clearance for an at-home cervical cancer screening tool, utilizing its HPV self-collection kit and assay—a significant step into the consumer-facing clinical market.
Sustainability and Operational Excellence
Waters continues to lead in lab sustainability, a growing priority for facility managers. The company reported exceeding its greenhouse gas emissions reduction target two years ahead of schedule, achieving a 36% reduction. Additionally, Waters has achieved a 50% decrease in landfill waste and earned the My Green Lab "Accountability, Consistency, and Transparency" (ACT) labels for several product lines.
This emphasis on "green" lab practices is becoming a standard procurement brief, similar to recent procurement and operations briefings seen from other major vendors like Thermo Fisher.
Procurement and Operations Briefing
For lab managers evaluating Waters as a partner in 2026, the Q1 results suggest several operational shifts:
Integrated Life Science Workflows: The combination of BD's flow cytometry and microbiology tools with Waters' mass spectrometry and chromatography creates a more unified supplier for labs involved in both cellular and molecular analysis.
Shift to High-Volume Regulated Testing: Waters' updated guidance and division structure indicate a priority on labs operating in regulated, high-volume environments (e.g., Clinical, Pharma QC, and Food Safety).
Synergy and Service: The company expects significant "revenue synergies" from the acquisition. Lab managers may see bundled service contracts or integrated informatics platforms (like the expansion of Empower Software) that bridge the gap between bioscience and analytical chemistry.
Waters Corporation remains in a strong financial position, raising its adjusted EPS guidance to $14.40–$14.60 for the full year. As the company continues to integrate its Biosciences and Diagnostics divisions, lab managers can expect a more aggressive push into automated, multi-omics workflows and highly regulated diagnostic platforms.
